Hazel M. Weir

AstraZeneca, Alderley Park
Macclesfield, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.

Journal: British journal of cancer

Published: April 25, 2018

A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2- Advanced Breast Cancer.

A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2- Advanced Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 20, 2017

Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.

Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.

Journal: Breast cancer research : BCR

Published: January 25, 2017

Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.

Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.

Journal: Cancer discovery

Published: December 23, 2015

Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.

Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.

Journal: Oncotarget

Published: October 09, 2015

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.

Journal: Journal of medicinal chemistry

Published: September 26, 2015

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.

Journal: Cancer research

Published: August 28, 2015

E-Cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin αvβ6 and maintained through TGFβ signalling.

E-Cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin αvβ6 and maintained through TGFβ signalling.

Journal: Oncogene

Published: July 29, 2013

MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo.

MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo.

Journal: Molecular cancer therapeutics

Published: June 09, 2012

A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo.

A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo.

Journal: Oncogene

Published: April 17, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026